Figure 3

Cognitive function in AD patients receiving rivastigmine 1 to 4 or 6 to 12 mg/day or placebo [33]. Values represent mean change from baseline. Both doses of rivastigmine were superior to placebo, although the higher doses provided more benefit. (From Corey-Bloom J Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease for the ENA 713 B352 Study Group. Int J Geriatr Psychopharmacol. 1998;1:55-65.)